Arterial hypertension and coronary heart disease treatment compliance – a key factor in cardiovascular mortality reduction
Abstract
The article is devoted to a problem of arterial hypertension and coronary heart disease treatment compliance. Various compliance aspects, related to patients, doctors, disease characteristics, pharmaceutical and non-pharmaceutical recommendations, are analyzed.
About the Authors
G. V. Pogosova
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
Yu. S. Belova
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
A. N. Roslavtseva
State Research Center for Preventive Medicine, State Federal Agency for Health and Social Development, Moscow
Russian Federation
Russian Federation
References
1. Оганов Р.Г., Масленникова Г.Я., Шальнова С.А. и др. Значение сердечно-сосудистых и других неинфекционных заболеваний для здоровья населения России. Профил забол укреп здор 2002; 2: 3-7.
2. Диагностика и лечение стабильной стенокардии. Российс- кие рекомендации. Разработаны Комитетом экспертов ВНОК 2004.
3. Оганов Р.Г., Масленникова Г.Я. Профилактика сердечно-сосудистых и других неинфекционных заболеваний – основа улучшения демографической ситуации в России. Кардиоваск тер профил 2005; 3(1): 4-9.
4. Sabate E. Adherence to long-term therapies: evidence for action. WHO, Geneva, 2003.
5. Hamilton G.A. Measuring adherence in a hypertension clinical trial. Eur J Cardiovasc Nurs 2003; 2(3): 219-28.
6. Neutel JM, Smith D.H. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens 2003; 5(2): 127-32.
7. Dusing R. Adverse events, compliance, and changes in therapy. Curr Hypertens Rep 2001; 3(6): 488-92.
8. Paramore LC, Halpern MT, Lapuerta P, et al. Impact of poorly controlled hypertension on healthcare resource utilization and cost. Am J Manag Care 2001; 7(4): 389-98.
9. Youssef RM, Moubarak II. Patterns and determinants of treatment compliance among hypertensive patients. East Mediterr Health J 2002; 8(4-5): 579-92.
10. Jokisalo E, Enlund H, Halonen P, et al. Factors related to poor control of blood pressure with antihypertensive drug therapy. Blood Press 2003; 12(1): 49-55.
11. Ragot S, Sosner P, Bouche G, et al. Appraisal of the knowledge of hypertensive patients and assessment of the role of the pharmacists in the management of hypertension: results of a regional survey. J Hum Hypertens 2005; 19(7): 577-84.
12. Svensson S, Kjellgren KI, Ahlner J, et al. Reasons for adherence with antihypertensive medication. Int J Cardiol 2000; 76(2-3): 157-63.
13. Werlemann BC, Offers E, Kolloch R. Herz. Compliance problems in therapy resistant. Нypertension 2004; 29 (3):271-5.
14. Jokisalo E, Kumpusalo E, Enlund H, et al. Patients’ perceived problems with hypertension and attitudes towards medical treatment. J Hum Hypertens 2001; 15(11): 755-61.
15. Nunes MI. The relationship between quality of life and adherence to treatment. Curr Hypertens Rep 2001; 3(6): 462-5.
16. Погосова Г.В. Депрессия – новый фактор риска ишемической болезни сердца и предиктор коронарной смерти. Кар- диология 2002; 4: 86-91.
17. Kim MT, Han HR, Hill MN, et al. Depression, substance use, adherence behaviors, and blood pressure in urban hypertensive black men. Ann Behav Med 2003; 26(1): 24-31.
18. Van Wijk BL, Klungel OH, Heerdink ER, et al. Rate and determinants of 10-year persistence with antihypertensive drugs. J Hypertens 2005; 23(11): 2101-7.
19. Yiannakopoulou ECh, Papadopulos JS, Cokkinos DV, et al. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005; 12(3): 243-9.
20. Schroeder K, Fahey T, Ebrahim S. Interventions for improving adherence to treatment in patients with high blood pressure in ambulatory settings. Cochrane Database Syst Rev 2004; 2: CD004804.
21. Ruzicka M, Leenen FH. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension. Drugs 2001; 61(7): 943-54.
22. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother 2005; 39(9): 1401-8.
23. Birtwhistle RV, Godwin MS, Delva MD, et al. Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ 2004; 328(7433): 204.
24. McCormick D, Gurwitz JH, Lessard D, et al. Use of aspirin, beta-blockers, and lipid-lowering medication before recurrent acute myocardial infarction: missed opportunities for prevention? Arch Intern Med 1999; 6: 561-7.
25. Allen LA, O’Donnell CJ, Giugliano RP, et al. Care concordant guidelines predicts decreased long-term mortality in patients with unstable angina pectoris and non-ST-elevation myocardial infarction. Am J Cardiol 2004; 93(10): 1218-22.
26. Chabot I, Moisan J, Gregoire JP, et al. Pharmacist intervention program for control of hypertension. Ann Pharmacother 2003; 37(9): 1186-93.
27. Wang L. Physician-related barriers to hypertension management. Med Princ Pract 2004; 13(5): 282-5.
28. Leibovitz E, Hertsog D, Oren S, et al. Lack of treatment continuance: an obstacle for controlling blood pressure. Harefuah 2005; 144(7): 467-70, 528, 527.
29. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001; 10(2): 62-73.
30. Neutel J, Smith D. Improving patient compliance: a major goal in the management of hypertension. J Clin Hypertens 2003; 5: 127-32.
31. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: principal results from EUROASPIRE II. Europ Heart J 2001; 22: 554-72.
32. De Velasco JA, Cosin J, Lopez-Sendon JL, et al. Nuevos datos sobre la prevencion secundaria del infarcto de miocardio en Espana. Resultados del estudio PREVERSE II. Rev Esp Cardio 2002; 55: 801-9.
33. Gitt AK, Wienbergen H, Schiele R, et al. Improvement in acute care of myocardial infarction in clinical practice 1994 – 2001 resulted in a 28% reduction of hospital mortality. Eur Heart J 2002; 4(Suppl ): 401.
34. Кобалава Ж.Д., Котовская Ю.В., Склизкова Л.А. и др. Представления об артериальной гипертонии у пожилых и реальная клиническая практика в России (Результаты I этапа российской научно-практической программы АРГУС). Кардиология 2001; 11: 14-20.
35. Леонова М.В., Белоусов Д.Ю. Результаты фармакоэпидемиологического исследования артериальной гипертонии в России (ПИФАГОР). Кардиология 2003; 11: 23-6.
36. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Особенности диагностики и терапии стабильной стенокардии в Российской Федерации (международное исследование ATP – Angina Treatment Pattern). Кардиология 2003; 5: 6-10.
37. Явелов И.С., Грацианский Н.А.Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме без подъемов сегмента ST. Кардиология 2003; 12: 23-36.
38. Явелов И.С., Грацианский Н.А.Российский регистр острых коронарных синдромов: лечение и исходы в стационаре при остром коронарном синдроме с подъемами сегмента ST. Кардиология 2004; 4: 4-13.
Review
For citations:
Pogosova G.V., Belova Yu.S., Roslavtseva A.N. Arterial hypertension and coronary heart disease treatment compliance – a key factor in cardiovascular mortality reduction. Cardiovascular Therapy and Prevention. 2007;6(1):99-104. (In Russ.)
Views:
613
Email this article 
